Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601)

Expert Opinion on Drug Delivery

Volumn 4, Issue 2, 2007, Pages 175-186

  Mamelak, Adam N ^a   Jacoby, Douglas B ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b TransMolecular Inc   (United States)

Author keywords

Chlorotoxin; Glioma; Intracavitary; Targeted therapy

Indexed keywords

CARMUSTINE; CHLOROTOXIN; CISPLATIN; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; IBRITUMOMAB TIUXETAN; INTERLEUKIN 13; IODINE 131; LOBRADIMIL; LOMUSTINE; MANNITOL; METHOTREXATE; PLASMINOGEN ACTIVATOR; PROCARBAZINE; PSEUDOMONAS EXOTOXIN; SCORPION VENOM; TEMOZOLOMIDE; TENASCIN; TM 601; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN INFECTION; BRAIN SURGERY; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; COVALENT BOND; CRAYFISH; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSARTHRIA; EXTERNAL BEAM RADIOTHERAPY; FACE DEFORMITY; FACE MALFORMATION; FEVER; FOLLOW UP; GLIOMA; GRAND MAL SEIZURE; HEADACHE; HUMAN; IMAGE ANALYSIS; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFUSION PUMP; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE PERMEABILITY; METASTASIS POTENTIAL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OUTCOME ASSESSMENT; PARESTHESIA; RADIATION INJURY; RADIOACTIVITY; SCORPION; SEIZURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERMODYNAMICS; THROMBOCYTOPENIA; TUMOR CELL; UNSPECIFIED SIDE EFFECT; WEAKNESS; WOUND INFECTION;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; EXPERT TESTIMONY; GLIOMA; HUMANS; IODINE RADIOISOTOPES; RABBITS; SCORPION VENOMS; TISSUE DISTRIBUTION;

EID: 33847776789     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.2.175     Document Type: Article

References (59)

1. CBTRUS: (2000) CBTRUS. Statistical Report: Primary Brain Tumors in the United States. (1992-1997).
2. OHGAKI H, KLEIHUES P: Epidemiology and etiology of gliomas. Acta Neuropathol. (Berl.) (2005) 109(1):93-108.
3. LAWS ER, PARNEY IF, HUANG W et al.: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. (2003) 99(3):467-473.
4. JOHANNESEN TB, LANGMARK F, LOTE K: Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J. Neurosurg. (2003) 99(5):854-862.
5. JEREMIC B, MILICIC B, GRUJICIC D et al.: Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am. J. Clin. Oncol. (2004)27(2):195-204.
6. BUCKNER JC: Factors influencing survival in high-grade gliomas. Semin. Oncol. (2003) 30(6 Suppl. 19):10-14.
7. KELLY PJ, DAUMAS-DUPORT C, KISPERT DB et al.: Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J. Neurosurg. (1987) 66(6):865-874.
8. GRIEB P: [5-Aminolevulinic acid (ALA) and its applications in neurosurgery]. Neurol. Neurochir. Pol. (2004) 38(3):201-207.
9. STUMMER W, NOVOTNY A, STEPP H et al.: Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. (2000) 93(6):1003-1013.
10. GORBACH AM, HEISS JD, KOPYLEV L, OLDFIELD EH: Intraoperative infrared imaging of brain tumors. J. Neurosurg. (2004) 101(6):960-969.
11. WITWER BP, MOFTAKHAR R, HASAN KM et al.: Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. J. Neurosurg. (2002) 97(3):568-575.
12. SAWAYA R: Extent of resection in malignant gliomas: a critical summary. J. Neurooncol. (1999) 42(3):303-305.
13. BUCCI MK, MAITYA, JANSS AJ et al.: Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer (2004) 101(4):817-824.
14. FISCHBACH AJ, MARTZ KL, NELSON JS et al.: Long-term survival in treated anaplastic astrocytomas. A report of combined RTOG/ECOG studies. Am. J. Clin. Oncol. (1991) 14(5):365-370.
15. SHORT SC: External beam and conformal radiotherapy in the management of gliomas. Acta Neurochir. Suppl. (2003) 88:37-43.
16. GROSSMAN SA, BATARA JF: Current management of glioblastoma multiforme. Semin. Oncol. (2004)31(5):635-644.
17. SHAPIRO WR, SHAPIRO JR: Biology and treatment of malignant glioma. Oncology (Huntingt.) (1998) 12(2):233-240; discussion 240, 246.
18. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
19. BREM H, PIANTADOSI S, BURGER PC et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet (1995) 345(8956):1008-1012.
20. BREM H, GABIKIAN P: Biodegradable polymet implants to treat brain tumors. J. Control. Release (2001) 74(1-3):63-67.
21. WESTPHAL M, LAMSZUS K, HILT D: Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir. Suppl. (2003) 88:61-67.
22. GURURANGAN S, COKGOR L, RICH JN et al.: Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-oncol. (2001) 3(4):246-250.
23. GARFIELD J, DAYAN AD, WELLER RO: Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin. Oncol. (1975) 1(3):213-222.
24. KLATZMANN D, VALERY CA, BENSIMON G et al.: A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. (1998) 9(17):2595-2604.
25. RAINOV NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. (2000) 11 (17):2389-2401.
26. SHAND N, WEBER F, MARIANI L et al.: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. (1999) 10(14):2325-2335.
27. TRASK TW, TRASK RP, AGUILAR-CORDOVA E et al.: Phase 1 study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. (2000) 1(2):195-203.
28. HASSENBUSCH SJ, NARDONE EM, LEVIN VA, LEEDS N, PlETRONIGRO D: Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia (2003) 5(1):9-16.
29. NEUWELT EA, DAHLBORG SA: Chemotherapy administered in conjunction with osmotic blood-brain barrier modification in patients with brain metastases. J. Neurooncol. (1987) 4 (3): 195-207.
30. BLACK KL, CLOUGHESY T, HUANG SC et al.: Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J. Neurosurg. (1997) 86(4):603-609.
31. TFAYLI A, HENTSCHEL P, MADAJEWICZ S et al.: Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. J. Neurooncol. (1999) 42(1):73-77.
32. MADAJEWICZ S, CHOWHAN N, ILIYA A et al.: Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer (1991) 67(11):2844-2849.
33. FEUN LG, LEE YY, YUNG WK, SAVARAJ N, WALLACE S: Intracarotid VP-16 in malignant brain tumors. J. Neurooncol. (1987) 4(4):397-401.
34. GREENBERG HS, ENSMINGER WD, CHANDLER WF et al.: Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J. Neurosurg. (1984) 61 (3):423-429.
35. LIEBERMAN DM, LASKE DW, MORRISON PF, BANKIEWICZ KS, OLDFIELD EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. (1995) 82(6): 1021-1029.
36. GILLIES GT, SMITH JH, HUMPHREY JA, BROADDUS WC: Positive pressure infusion of therapeutic agents into brain tissues: mathematical and experimental simulations. Technol. Health Care (2005) 13(4):235-243.
37. HADACZEK P, KOHUTNICKA M, KRAUZE MT et al.: Convection-enhanced delivery of adeno-associated virus type 2(AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. (2006) 17(3):291-302.
38. KUNWARS: Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir. Suppl. (2003) 88:105-111.
39. LESNIAK MS, BREM H: Targeted therapy for brain tumours. Nat. Rev. Drug Discov. (20O4) 3(6):499-508.
40. LIDAR Z, MARDOR Y, JONAS T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J. Neurosurg. (2004) 100(3):472-479.
41. MURO K, DAS S, RAIZER JJ: Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas. Technol. Cancer Res. Treat. (2006) 5(3):201-213.
42. LASKE DW, ROSSI P: Phase II multicenter trial of intratumoral/ interstitial therapy with TransMID in patients with refractory and progressive glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). Neuro-oncol. (2002) 4(Suppl. 2):558.
43. RUSTAMZADEH E, HALL WA, TODHUNTER DA et al.: Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice. Int. J. Cancer (2007) 120(2):411-419.
44. KUAN CT, WIKSTRAND CJ, BIGNER DD: EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. (2000) 17(2):71-78.
45. RAVIC M: Intracavitary treatment of malignant gliomas: radioimmunotherapy targeting fibronectin. Acta Neurochir. Suppl. (2003) 88:77-82.
46. 131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. (2002) 20(5): 1389-1397.
47. 131I-labeled 81C6 monoclonal antibody 81C6 administered into surgically created resection cavities in patients with malignant brain tumors. J. Nucl. Med. (1999) 40(4):631-638.
48. HOPKINS K, CHANDLER C, EATOUGH J, MOSS T, KEMSHEAD JT: Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40(4):835-844.
49. RIVA P, FRANCESCHI G, FRATTARELLI M et al.: Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin. Cancer Res. (1999) 5(10 Suppl.):3275s-3280s.
50. ULLRICH N, BORDEY A, GILLESPIE GY, SONTHEIMER H: Expression of voltage-activated chloride currents in acute slices of human gliomas. Neuroscience (1998) 83(4): 1161-1173.
51. SOROCEANU L, GILLESPIE Y, KHAZAELI MB, SONTHEIMER H: Use of chlorotoxin for targeting of primary brain tumors. Cancer Res. (1998) 58(21):4871-4879.
52. ULLRICH N, GILLESPIE GY, SONTHEIMER H: Human astrocytoma cells express a unique chloride current. Neuroreport (1996) 7(5):1020-1024.
53. ULLRICH N, SONTHEIMER H: Biophysical and pharmacological characterization of chloride currents in human astrocytoma cells. Am. J. Physiol. (1996) 270(5 Pt 1):C1511-C1521.
54. LYONS SA, O'NEAL J, SONTHEIMER H: Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia (2002) 39(2):162-173.
55. SOROCEANU L, MANNING TJ, Jr., SONTHEIMER H: Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. J. Neurosci. (1999) 19(14):5942-5954.
56. DESHANE J, GARNER CC, SONTHEIMER H: Chlorotoxin inhibits glioma cell invasion via matrix met alloproteinase-2. J. Biol. Chem. (2003) 278(6):4135-4144.
57. MCFERRIN MB, SONTHEIMER H: A role for ion channels in glioma cell invasion. Neuron Glia Biol. (2006) 2(1):39-49.
58. 131I-TM-601 in adult patients with recurrent high grade glioma. Neuro-oncol. (2003) Abstr. RA-19.
59. 131I-TM-601. J. Nucl. Med. (2005) 46(4):580-586.